LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

Search

Novo Nordisk A-S

Închisă

SectorSănătate

67.74 0.61

Rezumat

Modificarea prețului

24h

Curent

Minim

67.19

Maxim

68.3

Indicatori cheie

By Trading Economics

Venit

804M

29B

Vânzări

-7.6B

78B

P/E

Medie Sector

19.207

50.291

EPS

6.53

Randament dividend

2.32

Marjă de profit

37.182

Angajați

77,406

EBITDA

5.9B

46B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+40.74% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

2.32%

2.40%

Statistici piață

By TradingEconomics

Capitalizare de piață

43B

309B

Deschiderea anterioară

67.13

Închiderea anterioară

67.74

Sentimentul știrilor

By Acuity

80%

20%

359 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Novo Nordisk A-S Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

16 mai 2025, 11:36 UTC

Top știri

Novo Nordisk CEO to Step Down Amid Market Challenges

12 mai 2025, 09:36 UTC

Principalele dinamici ale pieței

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

7 mai 2025, 11:29 UTC

Top știri
Câștiguri
Principalele dinamici ale pieței

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

24 iun. 2025, 10:26 UTC

Market Talk

Novo Nordisk Sends Clear Message on Copycat Drugs -- Market Talk

23 iun. 2025, 13:09 UTC

Market Talk

Novo Nordisk Drug Data Doesn't Change Anything -- Market Talk

20 iun. 2025, 13:31 UTC

Achiziții, Fuziuni, Preluări

E.l.f. Beauty CEO Buys Up Smucker Stock -- Barrons.com

13 iun. 2025, 11:39 UTC

Market Talk

Novo Nordisk Skips to Late-Stage Development of New Obesity Drug -- Market Talk

13 iun. 2025, 10:04 UTC

Market Talk

Novo Nordisk Overtakes SAP to Reclaim Spot as Europe's Most Valuable Company -- Market Talk

11 iun. 2025, 09:45 UTC

Market Talk

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

10 iun. 2025, 13:38 UTC

Acțiuni populare

Stocks to Watch Tuesday: Tesla, TSMC, Novo Nordisk -- WSJ

9 iun. 2025, 10:09 UTC

Market Talk

Novo Nordisk Valuation Presents a Good Opportunity -- Market Talk

3 iun. 2025, 15:03 UTC

Achiziții, Fuziuni, Preluări

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

29 mai 2025, 01:00 UTC

Top știri

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

20 mai 2025, 14:08 UTC

Câștiguri

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

20 mai 2025, 07:43 UTC

Market Talk

Novo Nordisk Guidance at Risk After CEO News -- Market Talk

16 mai 2025, 18:35 UTC

Top știri

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 mai 2025, 17:34 UTC

Top știri

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 2nd Update

16 mai 2025, 13:42 UTC

Acțiuni populare

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16 mai 2025, 13:27 UTC

Market Talk

Novo Nordisk CEO Departure Comes as a Surprise -- Market Talk

16 mai 2025, 13:15 UTC

Top știri

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- Update

16 mai 2025, 12:17 UTC

Câștiguri

Novo Nordisk Chairman: No Link Between CEO Change and Other Recent Exec Departures

12 mai 2025, 22:14 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mai 2025, 18:45 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mai 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 mai 2025, 07:20 UTC

Market Talk

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

7 mai 2025, 15:13 UTC

Câștiguri

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

7 mai 2025, 13:56 UTC

Câștiguri

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 mai 2025, 13:45 UTC

Câștiguri

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

7 mai 2025, 11:25 UTC

Câștiguri

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

7 mai 2025, 11:18 UTC

Câștiguri

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

Comparație

Modificare preț

Novo Nordisk A-S Așteptări

Obiectiv de preț

By TipRanks

40.74% sus

Prognoză pe 12 luni

Medie 94.79 USD  40.74%

Maxim 142.564 USD

Minim 61 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNovo Nordisk A-S - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

8 ratings

4

Cumpărare

3

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

62.63 / 69.23Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

359 / 380 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.